Abeona Therapeutics Inc. (ABEO)
Chart Events
Performance Outlook
| Previous Close | 3.2500 |
| Open | 3.2300 |
| Bid | 2.9800 x 1800 |
| Ask | 3.0900 x 800 |
| Day's Range | 2.9700 - 3.2500 |
| 52 Week Range | 0.2700 - 30.0000 |
| Volume | |
| Avg. Volume | 183,751 |
| Market Cap | 444.253M |
| Beta (5Y Monthly) | 1.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9090 |
| Earnings Date | Mar 22, 2022 - Mar 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.67 |
- GlobeNewswire
Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 8:30 a.m. ET. The Company will also participate in one-on-one investor meetings at the conference. A live webcast of the fireside chat will be available on the Investors section of the Abeona website under "Even
- GlobeNewswire
Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a panel discussion at the Cantor Fitzgerald Cell and Genetic Medicines Conference on Thursday, September 15, 2022. The panel discussion, entitled, “Late Stage and Commercial Gene & Cell Therapy Warriors: How They Got to/Crossed the Finish Line,” is scheduled to begin at 2:30 p.m. ET. The Company will also par
- Insider Monkey
10 Best Penny Stocks to Buy in September
In this article, we discuss 10 best penny stocks to buy in September. If you want to see more stocks in this selection, check out 5 Best Penny Stocks to Buy in September. As the stock market runs red, investors are wary about spending copious amounts of money and making huge investments amid such macro […]
